» Articles » PMID: 10704418

Autoimmune-prone Mice Share a Promoter Haplotype Associated with Reduced Expression and Function of the Fc Receptor FcgammaRII

Overview
Journal Curr Biol
Publisher Cell Press
Specialty Biology
Date 2000 Mar 8
PMID 10704418
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Human autoimmune diseases thought to arise from the combined effects of multiple susceptibility genes include systemic lupus erythematosus (SLE) and autoimmune diabetes. Well-characterised polygenic mouse models closely resembling each of these diseases exist, and genetic evidence links receptors for the Fc portion of immunoglobulin G (FcR) with their pathogenesis in mice and humans [1] [2] [3]. FcRs may be activatory or inhibitory and regulate a variety of immune and inflammatory processes [4] [5]. FcgammaRII (CD32) negatively regulates activation of cells including B cells and macrophages [6]. FcgammaRII-deficient mice are prone to immune-mediated disease [7] [8] [9]. The gene encoding FcgammaRII, Fcgr2, is contained in genetic susceptibility intervals in mouse models of SLE such as the New Zealand Black (NZB) contribution to the (NZB x New Zealand White (NZW)) F1 strain [1] [10] [11] and the BXSB strain [12], and in human SLE [1] [2] [3]. We therefore sequenced Fcgr2 and identified a haplotype defined by deletions in the Fcgr2 promoter region that is present in major SLE-prone mouse strains (NZB, BXSB, SB/Le, MRL, 129 [13]) and non-obese diabetic (NOD) mice but absent in control strains (BALB/c, C57BL/6, DBA/2, C57BL/10) and NZW mice. The autoimmune haplotype was associated with reduced cell-surface expression of FcgammaRII on macrophages and activated B cells and with hyperactive macrophages resembling those of FcgammaRII-deficient mice, and is therefore likely to play an important role in the pathogenesis of SLE and possibly diabetes.

Citing Articles

Short- and long-term pathologic responses to quartz are induced by nearly free silanols formed during crystal fracturing.

Pavan C, Leinardi R, Benhida A, Ibouraadaten S, Yakoub Y, van den Brule S Part Fibre Toxicol. 2024; 21(1):52.

PMID: 39633374 PMC: 11619699. DOI: 10.1186/s12989-024-00611-8.


Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.

Dadas O, Ertay A, Cragg M Front Immunol. 2023; 14:1147467.

PMID: 37180119 PMC: 10167284. DOI: 10.3389/fimmu.2023.1147467.


Developmental trichloroethylene exposure enhances predictive markers of autoimmunity in a sex-specific manner in disease-resistant female mice.

Blossom S, Cabanlong C, Vyas K Toxicol Appl Pharmacol. 2022; 454:116233.

PMID: 36096280 PMC: 9650993. DOI: 10.1016/j.taap.2022.116233.


FcγRIIB regulates autoantibody responses by limiting marginal zone B cell activation.

Barlev A, Malkiel S, Kurata-Sato I, Dorjee A, Suurmond J, Diamond B J Clin Invest. 2022; 132(17).

PMID: 35819855 PMC: 9435648. DOI: 10.1172/JCI157250.


Meant to B: B cells as a therapeutic target in systemic lupus erythematosus.

Atisha-Fregoso Y, Toz B, Diamond B J Clin Invest. 2021; 131(12).

PMID: 34128474 PMC: 8203443. DOI: 10.1172/JCI149095.